StageZero Life Sciences Ltd: StageZero Announces Fourth Quarter 2019 Results and Year End Investor Call

TORONTO, ON / ACCESSWIRE / May 19, 2020 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) today announced that it will host a conference call and online presentation at 5:00 pm ET on May 19th to review the Fourth Quarter and Full Year 2019 operational results and to discuss business developments to date.

The Company states that the delay in the filings has resulted from a difference in opinions between the Company's previous auditors and our current auditors, BDO, relating to the following two items.

1. The company's common share warrants are considered to be derivative liabilities due to the warrants being exercisable in a currency (Canadian dollar) other than the functional currency of the Company (US Dollar). Accordingly, the warrants are measured at fair value at each reporting date, with changes in fair value included in the consolidated statements of loss and comprehensive loss for the applicable reporting period.
2. Treatment of Goodwill related to the acquisition of the lab in 2016.

There are no adverse business events related to the Company.

Fourth Quarter 2019 Results Conference Call Details:
Event Date: Tuesday, May 19, 2020
Time: 5:00PM EST
Participant: [phone] | [phone]
Replay: (877)-481-4010 | PIN 34859
International Replay: (919)-882-2331
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/34859

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (nasal swab) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phlebotomist who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Company Contacts:

James R. Howard-Tripp
Chairman & CEO
[e-mail]
Tel: [phone] Ext. 1

Rebecca Greco
Investor Relations
[e-mail]
Tel: [phone] Ext. 1838

SOURCE: StageZero Life Sciences Ltd

View source version on accesswire.com:
https://www.accesswire.com/590442/CORRECTION-StageZero-Announces-Fourth-Quarter-2019-Results-and-Year-End-Investor-Call